Report cover image

Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 119 Pages
SKU # APRC20543482

Description

Summary

According to APO Research, The global Tumor Necrosis Factor (TNF) Inhibitor Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Tumor Necrosis Factor (TNF) Inhibitor Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Tumor Necrosis Factor (TNF) Inhibitor Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Tumor Necrosis Factor (TNF) Inhibitor Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Tumor Necrosis Factor (TNF) Inhibitor Drugs include Johnson & Johnson Services, Inc., Merck & co., Inc., Pfizer, Inc., Amgen Inc., AbbVie Inc., UCB S.A. and Novartis International AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Necrosis Factor (TNF) Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Necrosis Factor (TNF) Inhibitor Drugs.The Tumor Necrosis Factor (TNF) Inhibitor Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Tumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Company
Johnson & Johnson Services, Inc. Merck & co., Inc. Pfizer, Inc. Amgen Inc. AbbVie Inc. UCB S.A. Novartis International AGTumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Type
Biosimilars Simponi/Simponi Aria Remicade Humira Enbrel CimziaTumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Application
Psoriatic Arthritis Psoriasis Juvenile Idiopathic Arthritis Ankylosing Spondylitis Rheumatoid Arthritis Ulcerative Colitis Crohn’s Disease Hidradenitis Suppurativa OthersTumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Application
Psoriatic Arthritis Psoriasis Juvenile Idiopathic Arthritis Ankylosing Spondylitis Rheumatoid Arthritis Ulcerative Colitis Crohn’s Disease Hidradenitis Suppurativa OthersTumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Spain Russia Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Middle East & Africa Saudi Arabia Israel United Arab Emirates Turkey Iran Egypt

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor (TNF) Inhibitor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor (TNF) Inhibitor Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Tumor Necrosis Factor (TNF) Inhibitor Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

119 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Biosimilars
2.2.3 Simponi/Simponi Aria
2.2.4 Remicade
2.2.5 Humira
2.2.6 Enbrel
2.2.7 Cimzia
2.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Psoriatic Arthritis
2.3.3 Psoriasis
2.3.4 Juvenile Idiopathic Arthritis
2.3.5 Ankylosing Spondylitis
2.3.6 Rheumatoid Arthritis
2.3.7 Ulcerative Colitis
2.3.8 Crohn’s Disease
2.3.9 Hidradenitis Suppurativa
2.3.10 Others
2.4 Assumptions and Limitations
3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Breakdown Data by Type
3.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic Market Size by Type (2020-2025)
3.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Type (2026-2031)
4 Tumor Necrosis Factor (TNF) Inhibitor Drugs Breakdown Data by Application
4.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic Market Size by Application (2020-2025)
4.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Perspective (2020-2031)
5.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Growth Trends by Region
5.2.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic Market Size by Region (2020-2025)
5.2.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Region (2026-2031)
5.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Dynamics
5.3.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Trends
5.3.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Drivers
5.3.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Challenges
5.3.4 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Tumor Necrosis Factor (TNF) Inhibitor Drugs Players by Revenue
6.1.1 Global Top Tumor Necrosis Factor (TNF) Inhibitor Drugs Players by Revenue (2020-2025)
6.1.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Players (2020-2025)
6.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Tumor Necrosis Factor (TNF) Inhibitor Drugs Head Office and Area Served
6.4 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Players, Product Type & Application
6.5 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Manufacturers Established Date
6.6 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2020-2031)
7.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025)
7.4 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2020-2031)
8.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025)
8.4 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2020-2031)
9.2 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025)
9.4 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2020-2031)
10.2 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025)
10.4 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2020-2031)
11.2 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025)
11.4 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Johnson & Johnson Services, Inc.
12.1.1 Johnson & Johnson Services, Inc. Company Information
12.1.2 Johnson & Johnson Services, Inc. Business Overview
12.1.3 Johnson & Johnson Services, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
12.1.4 Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
12.1.5 Johnson & Johnson Services, Inc. Recent Developments
12.2 Merck & co., Inc.
12.2.1 Merck & co., Inc. Company Information
12.2.2 Merck & co., Inc. Business Overview
12.2.3 Merck & co., Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
12.2.4 Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
12.2.5 Merck & co., Inc. Recent Developments
12.3 Pfizer, Inc.
12.3.1 Pfizer, Inc. Company Information
12.3.2 Pfizer, Inc. Business Overview
12.3.3 Pfizer, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
12.3.4 Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
12.3.5 Pfizer, Inc. Recent Developments
12.4 Amgen Inc.
12.4.1 Amgen Inc. Company Information
12.4.2 Amgen Inc. Business Overview
12.4.3 Amgen Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
12.4.4 Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
12.4.5 Amgen Inc. Recent Developments
12.5 AbbVie Inc.
12.5.1 AbbVie Inc. Company Information
12.5.2 AbbVie Inc. Business Overview
12.5.3 AbbVie Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
12.5.4 AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
12.5.5 AbbVie Inc. Recent Developments
12.6 UCB S.A.
12.6.1 UCB S.A. Company Information
12.6.2 UCB S.A. Business Overview
12.6.3 UCB S.A. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
12.6.4 UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
12.6.5 UCB S.A. Recent Developments
12.7 Novartis International AG
12.7.1 Novartis International AG Company Information
12.7.2 Novartis International AG Business Overview
12.7.3 Novartis International AG Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
12.7.4 Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
12.7.5 Novartis International AG Recent Developments
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 6. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type (2020-2025)
Table 7. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 8. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type (2026-2031)
Table 9. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 10. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Application (2020-2025)
Table 11. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 12. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Application (2026-2031)
Table 13. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 14. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 15. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Region (2020-2025)
Table 16. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 17. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Region (2026-2031)
Table 18. Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Trends
Table 19. Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Drivers
Table 20. Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Opportunities and Challenges
Table 21. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints
Table 22. Global Top Tumor Necrosis Factor (TNF) Inhibitor Drugs Players by Revenue (US$ Million) & (2020-2025)
Table 23. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Players (2020-2025)
Table 24. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
Table 25. Global Key Players of Tumor Necrosis Factor (TNF) Inhibitor Drugs, Headquarters and Area Served
Table 26. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 32. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 33. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 34. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 35. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 36. Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 37. Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 38. Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 39. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 40. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 41. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 42. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 45. Johnson & Johnson Services, Inc. Company Information
Table 46. Johnson & Johnson Services, Inc. Business Overview
Table 47. Johnson & Johnson Services, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025) & (US$ Million)
Table 48. Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
Table 49. Johnson & Johnson Services, Inc. Recent Developments
Table 50. Merck & co., Inc. Company Information
Table 51. Merck & co., Inc. Business Overview
Table 52. Merck & co., Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025) & (US$ Million)
Table 53. Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
Table 54. Merck & co., Inc. Recent Developments
Table 55. Pfizer, Inc. Company Information
Table 56. Pfizer, Inc. Business Overview
Table 57. Pfizer, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025) & (US$ Million)
Table 58. Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
Table 59. Pfizer, Inc. Recent Developments
Table 60. Amgen Inc. Company Information
Table 61. Amgen Inc. Business Overview
Table 62. Amgen Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025) & (US$ Million)
Table 63. Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
Table 64. Amgen Inc. Recent Developments
Table 65. AbbVie Inc. Company Information
Table 66. AbbVie Inc. Business Overview
Table 67. AbbVie Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025) & (US$ Million)
Table 68. AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
Table 69. AbbVie Inc. Recent Developments
Table 70. UCB S.A. Company Information
Table 71. UCB S.A. Business Overview
Table 72. UCB S.A. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025) & (US$ Million)
Table 73. UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
Table 74. UCB S.A. Recent Developments
Table 75. Novartis International AG Company Information
Table 76. Novartis International AG Business Overview
Table 77. Novartis International AG Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025) & (US$ Million)
Table 78. Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Portfolio
Table 79. Novartis International AG Recent Developments
Table 80. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Image
Figure 5. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 6. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Type: 2024 VS 2031
Figure 7. Biosimilars Product
Figure 8. Simponi/Simponi Aria Product
Figure 9. Remicade Product
Figure 10. Humira Product
Figure 11. Enbrel Product
Figure 12. Cimzia Product
Figure 13. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2025-2031) & (US$ Million)
Figure 14. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application: 2024 VS 2031
Figure 15. Psoriatic Arthritis Product
Figure 16. Psoriasis Product
Figure 17. Juvenile Idiopathic Arthritis Product
Figure 18. Ankylosing Spondylitis Product
Figure 19. Rheumatoid Arthritis Product
Figure 20. Ulcerative Colitis Product
Figure 21. Crohn’s Disease Product
Figure 22. Hidradenitis Suppurativa Product
Figure 23. Others Product
Figure 24. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 25. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 26. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Region: 2024 VS 2031
Figure 27. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Players in 2024
Figure 28. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Manufacturers Established Date
Figure 29. Global Top 5 and 10 Tumor Necrosis Factor (TNF) Inhibitor Drugs Players Market Share by Revenue in 2024
Figure 30. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 31. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2020-2031)
Figure 33. United States Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Canada Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Mexico Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2020-2031)
Figure 36. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2020-2031)
Figure 38. Germany Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. France Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. U.K. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Italy Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Spain Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Russia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Netherlands Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Nordic Countries Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2020-2031)
Figure 48. China Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Japan Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. South Korea Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. India Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. India Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2020-2031)
Figure 53. Australia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. China Taiwan Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Southeast Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2020-2031)
Figure 58. Brazil Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 59. Argentina Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 60. Chile Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 61. Colombia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 62. Peru Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 63. Johnson & Johnson Services, Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
Figure 64. Merck & co., Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
Figure 65. Pfizer, Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
Figure 66. Amgen Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
Figure 67. AbbVie Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
Figure 68. UCB S.A. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
Figure 69. Novartis International AG Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2020-2025)
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.